Publication Database

Expression of mutated BRAFV595E kinase in canine carcinomas (2024)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Bartel, Annika

Aupperle-Lellbach, Heike

Kehl, Alexandra

Weidle, Silvia

Aeschlimann, Leonore

Klopfleisch, R (WE 12)

Brot, Simone de

Quelle

Veterinary sciences

Bandzählung: 11

Heftzählung: 11

Seiten: 584

ISSN: 2306-7381

Sprache

Englisch

Verweise

URL (Volltext): https://www.mdpi.com/2306-7381/11/11/584

DOI: 10.3390/vetsci11110584

Pubmed: 39591358

Kontakt

Institut für Tierpathologie

Robert-von-Ostertag-Str. 15
14163 Berlin
+49 30 838 62450
pathologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Alterations of the BRAF gene and the resulting changes in the BRAF protein are one example of molecular cancer profiling in humans and dogs. We tested 227 samples of canine carcinomas from different anatomical sites (anal sac (n = 23), intestine (n = 21), liver (n = 21), lungs (n = 19), mammary gland (n = 20), nasal cavity (n = 21), oral epithelium (n = 18), ovary (n = 20), prostate (n = 21), thyroid gland (n = 21), urinary bladder (n = 22)) with two commercially available primary anti-BRAFV600E antibodies (VE1 Ventana, VE1 Abcam). The immunohistochemical results were confirmed with droplet digital PCR (ddPCR). BRAFV595E-mutated cases were found in canine prostatic (16/21), urothelial (17/22), and oral squamous cell carcinomas (4/18), while other carcinoma types tested negative. Both antibodies showed consistent results, with intracytoplasmic immunolabeling of tumour cells, making them reliable tools for detecting the BRAFV595E mutation in canine carcinomas. In conclusion, identifying BRAF mutations from biopsy material offers a valuable opportunity to enhance cancer treatment strategies (BRAF inhibitors) in canine urothelial carcinomas, prostatic carcinomas, and oral squamous cell carcinomas.